NovoCure Limited

NasdaqGS:NVCR Stock Report

Market Cap: US$3.3b

NovoCure Valuation

Is NVCR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NVCR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NVCR ($30.8) is trading below our estimate of fair value ($77.43)

Significantly Below Fair Value: NVCR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NVCR?

Key metric: As NVCR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NVCR. This is calculated by dividing NVCR's market cap by their current revenue.
What is NVCR's PS Ratio?
PS Ratio5.8x
SalesUS$577.74m
Market CapUS$3.33b

Price to Sales Ratio vs Peers

How does NVCR's PS Ratio compare to its peers?

The above table shows the PS ratio for NVCR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.4x
NVST Envista Holdings
1.3x2.8%US$3.2b
QDEL QuidelOrtho
1.1x1.0%US$3.0b
LIVN LivaNova
2.1x4.4%US$2.6b
ENOV Enovis
1.2x7.3%US$2.4b
NVCR NovoCure
5.8x11.7%US$3.3b

Price-To-Sales vs Peers: NVCR is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (1.4x).

Price to Sales Ratio vs Industry

How does NVCR's PS Ratio compare vs other companies in the US Medical Equipment Industry?

49 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.6x4.4%US$201.98m
ARAY Accuray
0.4x5.5%US$186.05m
NVRO Nevro
0.3x2.8%US$142.02m
RMTI Rockwell Medical
0.7x-7.3%US$67.22m
NVCR 5.8xIndustry Avg. 3.2xNo. of Companies49PS02.85.68.411.214+
49 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NVCR is expensive based on its Price-To-Sales Ratio (5.8x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is NVCR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NVCR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ratio4.5x

Price-To-Sales vs Fair Ratio: NVCR is expensive based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (4.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NVCR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$30.80
US$35.00
+13.6%
13.7%US$42.00US$29.00n/a7
Dec ’25US$20.04
US$26.71
+33.3%
25.8%US$40.00US$18.00n/a7
Nov ’25US$16.18
US$26.71
+65.1%
25.8%US$40.00US$18.00n/a7
Oct ’25US$14.89
US$25.43
+70.8%
27.2%US$40.00US$18.00n/a7
Sep ’25US$19.44
US$25.86
+33.0%
25.2%US$40.00US$18.00n/a7
Aug ’25US$21.40
US$25.86
+20.8%
25.2%US$40.00US$18.00n/a7
Jul ’25US$17.35
US$26.36
+51.9%
32.4%US$42.00US$14.50n/a7
Jun ’25US$22.01
US$25.93
+17.8%
33.7%US$42.00US$14.50n/a7
May ’25US$12.74
US$25.86
+103.0%
34.4%US$42.00US$15.00n/a7
Apr ’25US$15.49
US$26.43
+70.6%
41.0%US$49.00US$15.00n/a7
Mar ’25US$16.25
US$25.00
+53.8%
43.0%US$49.00US$15.00n/a7
Feb ’25US$14.66
US$26.14
+78.3%
45.5%US$49.00US$14.00n/a7
Jan ’25US$14.93
US$26.14
+75.1%
45.2%US$49.00US$15.00n/a7
Dec ’24US$12.50
US$26.14
+109.1%
45.2%US$49.00US$15.00US$20.047
Nov ’24US$13.10
US$28.83
+120.1%
39.4%US$49.00US$15.00US$16.186
Oct ’24US$16.15
US$35.17
+117.8%
27.6%US$49.00US$23.00US$14.896
Sep ’24US$22.29
US$35.17
+57.8%
27.6%US$49.00US$23.00US$19.446
Aug ’24US$32.65
US$62.20
+90.5%
42.6%US$102.00US$33.00US$21.405
Jul ’24US$41.50
US$67.00
+61.4%
36.6%US$104.00US$38.00US$17.355
Jun ’24US$74.90
US$76.29
+1.9%
35.0%US$115.00US$38.00US$22.017
May ’24US$66.92
US$82.00
+22.5%
36.9%US$130.00US$40.00US$12.747
Apr ’24US$60.14
US$96.75
+60.9%
49.8%US$200.00US$40.00US$15.498
Mar ’24US$76.28
US$102.88
+34.9%
43.6%US$200.00US$40.00US$16.258
Feb ’24US$91.12
US$103.75
+13.9%
43.3%US$200.00US$42.00US$14.668
Jan ’24US$73.35
US$91.50
+24.7%
50.8%US$200.00US$42.00US$14.938
Dec ’23US$81.54
US$91.25
+11.9%
50.9%US$200.00US$42.00US$12.508

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:12
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI